secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000875045-23-000035
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q3 GAAP loss $0.47/sh, revenue $2.53B; updates FY guidance, highlights LEQEMBI
--------------------------------------------------------------------------------

- Revenue $2.53B (+1% YoY, +3% CC); GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36 (-9% YoY).
- LEQEMBI FDA approval for Alzheimer's, ZURZUVAE for PPD approved; Reata acquisition closed.
- Fit for Growth cost savings program of $1B initiated to improve bottom line.
- Full-year 2023 guidance updated; new launches expected to drive growth.
- Subcutaneous LEQEMBI and tau-directed ASO (BIIB080) show clinical potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504523000035/0000875045-23-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504523000035/biib-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000875045-23-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer